Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches.

Nat Commun · 2017 · PMC5709430 · PMID 29192144

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

FSHD2 patients showed a trend to express more ACVRIIB than FSHD1 (+120%, p = 0.08).

also in 53,322 other papers

an important trendno p-value reported

Associated with this GDF8 decrease, an important trend to an increase of circulating FSTN was observed (SMA 135.6% ± 71.3 and DMD 189.4% ± 35.2 compared with controls, respectively) (Fig. 1d ).

also in 1,052 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.